Keith A. Rodvold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Keith A. Rodvold has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
Mark H. Gotfried
Pulmonary Associates, PA
14 shared publicationsLarry H. Danziger
College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA
7 shared publicationsEric Wenzler
University of Illinois at Chicago, College of Pharmacy
5 shared publications- Eric Wenzler
University of Illinois at Chicago, Chicago, Illinois
4 shared publications Manjunath P. Pai
College of Pharmacy, University of Michigan, Ann Arbor, MI, USA
4 shared publicationsAshima Bhatia
Wockhardt Ltd., Mumbai, India
3 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (10)
Impact of renal impairment on pharmacokinetics, safety, and tolerability of funobactam, combined with imipenem and cilastatin
A phase 1, open-label study was conducted to investigate the effect of renal impairment (RI) on pharmacokinetics (PK) and safety of funobactam plus imipenem/cilastatin. Participants were enrolled and assigned to one of five cohorts based on renal function category: normal renal function, mild RI, moderate RI, severe RI, and end-stage renal disease (ESRD) requiring hemodialysis (HD). Participants received a single-dose of funobactam with imipenem and cilastatin by intravenous infusion administered over 60 min. Serial blood and urine samples were collected for non-compartmental PK analysis. Compared to participants with normal renal function, the geometric mean ratio (90% confidence interval) of plasma area under the curve (AUC0-∞) for funobactam, imipenem, and cilastatin increased with RI from mild (1.32 [1.04, 1.66], 1.37 [1.04, 1.79], and 1.27 [0.90, 1.78], respectively) to ESRD requiring HD (9.58 [7.59, 12.10], 2.69 [2.06, 3.52], and 15.15 [10.8, 21.3], respectively). The renal clearance for funobactam, imipenem, and cilastatin decreased progressively from normal renal function (3.93 ± 1.12 L/h, 4.95 ± 2.40 L/h, and 6.98 ± 2.75 L/h, respectively) to severe RI (0.94 ± 0.37 L/h, 1.16 ± 0.34 L/h, and 1.70 ± 0.60 L/h, respectively). Plasma clearance of funobactam, imipenem, and cilastatin correlated (r ≥0.93) with creatinine clearance and the estimated glomerular filtration rate. The treatment was well tolerated, with no deaths, severe adverse events, or discontinuation due to adverse events. Dosage adjustments of funobactam, imipenem, and cilastatin will be needed in patients with renal impairment or ESRD requiring HD. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04787562 .
- 7 October 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (10)
Open AccessImpact of renal impairment on pharmacokinetics, safety, and tolerability of funobactam, combined with imipenem and cilastatin
A phase 1, open-label study was conducted to investigate the effect of renal impairment (RI) on pharmacokinetics (PK) and safety of funobactam plus imipenem/cilastatin. Participants were enrolled and assigned to one of five cohorts based on renal function category: normal renal function, mild RI, moderate RI, severe RI, and end-stage renal disease (ESRD) requiring hemodialysis (HD). Participants received a single-dose of funobactam with imipenem and cilastatin by intravenous infusion administered over 60 min. Serial blood and urine samples were collected for non-compartmental PK analysis. Compared to participants with normal renal function, the geometric mean ratio (90% confidence interval) of plasma area under the curve (AUC0-∞) for funobactam, imipenem, and cilastatin increased with RI from mild (1.32 [1.04, 1.66], 1.37 [1.04, 1.79], and 1.27 [0.90, 1.78], respectively) to ESRD requiring HD (9.58 [7.59, 12.10], 2.69 [2.06, 3.52], and 15.15 [10.8, 21.3], respectively). The renal clearance for funobactam, imipenem, and cilastatin decreased progressively from normal renal function (3.93 ± 1.12 L/h, 4.95 ± 2.40 L/h, and 6.98 ± 2.75 L/h, respectively) to severe RI (0.94 ± 0.37 L/h, 1.16 ± 0.34 L/h, and 1.70 ± 0.60 L/h, respectively). Plasma clearance of funobactam, imipenem, and cilastatin correlated (r ≥0.93) with creatinine clearance and the estimated glomerular filtration rate. The treatment was well tolerated, with no deaths, severe adverse events, or discontinuation due to adverse events. Dosage adjustments of funobactam, imipenem, and cilastatin will be needed in patients with renal impairment or ESRD requiring HD. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04787562 .
- Open Access
- 15 June 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0052426
Plasma and intrapulmonary pharmacokinetics of funobactam, a novel diazabicyclooctane β-lactamase inhibitor, administered in combination with imipenem/cilastatin in healthy subjects
Funobactam (formerly XNW4107) is a novel non-β-lactam diazabicyclooctane β-lactamase inhibitor with potent direct activity against Ambler classes A, C, and D β-lactamases. Imipenem in combination with funobactam exhibits robust activity against carbapenem-resistant Enterobacterales , Acinetobacter baumannii , and Pseudomonas aeruginosa . This study evaluated the intrapulmonary pharmacokinetics of funobactam, imipenem, and cilastatin in healthy subjects. Twenty participants received a 60 min intravenous infusion of imipenem 500 mg/cilastatin 500 mg combined with funobactam 250 mg every 6 h for five doses. Bronchoalveolar lavage (BAL) was performed at 1, 2, 4, or 6 h after the fifth dose ( n = 5 per sampling time point) to determine epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations. The means from each plasma sampling time corresponding to the BAL sampling time were used to estimate the area under the curve from 0 to 6 h (AUC 0–6h ) for plasma, and mean concentrations from BAL sampling times from each cohort were used to estimate AUC 0–6h for ELF and AM concentrations. Intrapulmonary penetration was assessed using AUC 0–6h ratios of ELF and AM to unbound plasma. The AUC 0–6h ratios of ELF to unbound plasma for funobactam, imipenem, and cilastatin were 35.2%, 31.8%, and 23.0%, respectively, and the AUC 0–6h ratios of AM to unbound plasma were 36.6%, 16.8%, and 17.9%, respectively. Funobactam penetrated ELF and AM and exhibited higher intrapulmonary penetration than imipenem and cilastatin, supporting the clinical evaluation of funobactam in combination with imipenem for the treatment of nosocomial pneumonia. This study is registered with ClinicalTrials.gov as NCT04802863 .
- 15 June 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0052426
Open AccessPlasma and intrapulmonary pharmacokinetics of funobactam, a novel diazabicyclooctane β-lactamase inhibitor, administered in combination with imipenem/cilastatin in healthy subjects
Funobactam (formerly XNW4107) is a novel non-β-lactam diazabicyclooctane β-lactamase inhibitor with potent direct activity against Ambler classes A, C, and D β-lactamases. Imipenem in combination with funobactam exhibits robust activity against carbapenem-resistant Enterobacterales , Acinetobacter baumannii , and Pseudomonas aeruginosa . This study evaluated the intrapulmonary pharmacokinetics of funobactam, imipenem, and cilastatin in healthy subjects. Twenty participants received a 60 min intravenous infusion of imipenem 500 mg/cilastatin 500 mg combined with funobactam 250 mg every 6 h for five doses. Bronchoalveolar lavage (BAL) was performed at 1, 2, 4, or 6 h after the fifth dose ( n = 5 per sampling time point) to determine epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations. The means from each plasma sampling time corresponding to the BAL sampling time were used to estimate the area under the curve from 0 to 6 h (AUC 0–6h ) for plasma, and mean concentrations from BAL sampling times from each cohort were used to estimate AUC 0–6h for ELF and AM concentrations. Intrapulmonary penetration was assessed using AUC 0–6h ratios of ELF and AM to unbound plasma. The AUC 0–6h ratios of ELF to unbound plasma for funobactam, imipenem, and cilastatin were 35.2%, 31.8%, and 23.0%, respectively, and the AUC 0–6h ratios of AM to unbound plasma were 36.6%, 16.8%, and 17.9%, respectively. Funobactam penetrated ELF and AM and exhibited higher intrapulmonary penetration than imipenem and cilastatin, supporting the clinical evaluation of funobactam in combination with imipenem for the treatment of nosocomial pneumonia. This study is registered with ClinicalTrials.gov as NCT04802863 .
- Open Access
- 3 June 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (6) , e0195025
Plasma and intrapulmonary pharmacokinetics of ceftibuten and ledaborbactam in healthy male and female adults
Ledaborbactam etzadroxil (LED-E) is an oral prodrug of ledaborbactam, a broad-spectrum β-lactamase inhibitor. In combination with ceftibuten (CTB), a third-generation oral cephalosporin, LED-E represents a potential oral β-lactam/β-lactamase inhibitor regimen for treating infections caused by drug-resistant Gram-negative pathogens. This phase 1, single-center, open-label study evaluated intrapulmonary concentrations of ledaborbactam (LED) and CTB in healthy adults. Participants in Group 1 received five oral doses of CTB/LED-E (600 mg/600 mg) every 12 h (q12h), and participants in Group 2 received five oral doses of CTB 600 mg q12h. Following the fifth dose, participants underwent a standardized single bronchoscopy with bronchoalveolar lavage (BAL). Twenty-eight participants in Group 1 and six participants in Group 2 were randomized and dosed. Among participants receiving CTB/LED-E, epithelial lining fluid (ELF) area under the concentration-time curve from 0 to 12 h (AUC 0–12 ) for aspirate 1 was 14,867 ng·h/mL for CTB and 14,529 ng·h/mL for LED, and for pooled aspirates 2 + 3 + 4 was 10,486 ng·h/mL and 9,809 ng·h/mL, respectively. ELF-to-unbound plasma AUC ratios were 0.341 (aspirate 1) and 0.239 (pooled aspirates 2 + 3 + 4) for CTB and 1.560 and 1.032, respectively, for LED. Participants receiving CTB alone demonstrated similar lung penetration, indicating no effect of LED on CTB exposure. Both CTB/LED-E and CTB alone were safe and well tolerated; all adverse events were mild or moderate and unrelated to study drug. These results demonstrate pulmonary penetration of CTB and LED and support further evaluation of CTB/LED-E for the treatment of lower respiratory tract bacterial infections caused by susceptible pathogens. This study is registered with ClinicalTrials.gov as NCT06665555 .
- 3 June 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (6) , e0195025
Open AccessPlasma and intrapulmonary pharmacokinetics of ceftibuten and ledaborbactam in healthy male and female adults
Ledaborbactam etzadroxil (LED-E) is an oral prodrug of ledaborbactam, a broad-spectrum β-lactamase inhibitor. In combination with ceftibuten (CTB), a third-generation oral cephalosporin, LED-E represents a potential oral β-lactam/β-lactamase inhibitor regimen for treating infections caused by drug-resistant Gram-negative pathogens. This phase 1, single-center, open-label study evaluated intrapulmonary concentrations of ledaborbactam (LED) and CTB in healthy adults. Participants in Group 1 received five oral doses of CTB/LED-E (600 mg/600 mg) every 12 h (q12h), and participants in Group 2 received five oral doses of CTB 600 mg q12h. Following the fifth dose, participants underwent a standardized single bronchoscopy with bronchoalveolar lavage (BAL). Twenty-eight participants in Group 1 and six participants in Group 2 were randomized and dosed. Among participants receiving CTB/LED-E, epithelial lining fluid (ELF) area under the concentration-time curve from 0 to 12 h (AUC 0–12 ) for aspirate 1 was 14,867 ng·h/mL for CTB and 14,529 ng·h/mL for LED, and for pooled aspirates 2 + 3 + 4 was 10,486 ng·h/mL and 9,809 ng·h/mL, respectively. ELF-to-unbound plasma AUC ratios were 0.341 (aspirate 1) and 0.239 (pooled aspirates 2 + 3 + 4) for CTB and 1.560 and 1.032, respectively, for LED. Participants receiving CTB alone demonstrated similar lung penetration, indicating no effect of LED on CTB exposure. Both CTB/LED-E and CTB alone were safe and well tolerated; all adverse events were mild or moderate and unrelated to study drug. These results demonstrate pulmonary penetration of CTB and LED and support further evaluation of CTB/LED-E for the treatment of lower respiratory tract bacterial infections caused by susceptible pathogens. This study is registered with ClinicalTrials.gov as NCT06665555 .
- Open Access
- 26 June 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (5) , e285-e293
Pivmecillinam for Treatment of Uncomplicated Urinary Tract Infection: New Efficacy Analysis
Background: In April 2024—over 40 years after its first approval in Europe—pivmecillinam received approval from the United States Food and Drug Administration (FDA) for the treatment of uncomplicated urinary tract infection (uUTI) in women aged ≥18 years, caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. Herein, we describe the reanalysis from previously published clinical trials, conducted in accordance with current FDA efficacy criteria, which formed the basis for this regulatory approval. Methods: Of 14 studies reviewed, 3 randomized, controlled trials offered suitable subject-level data from patients with uUTI treated with 185 mg pivmecillinam 3 times daily for 3–7 days. Efficacy endpoints for reanalysis were rates of overall (composite clinical and microbiological), clinical, and microbiological response in the microbiological intention-to-treat population (urine culture ≥105 colony-forming units/mL; ≤2 microorganism species; no baseline pathogen nonsusceptible to active comparator). Results: Across the 3 primary studies, overall success rates with pivmecillinam at test of cure (Days 7–15) were 62.0%–71.7% (clinical success, 63.5%–82.7%; microbiological success, 74.3%–86.9%). Overall success was higher for pivmecillinam than for placebo (95% confidence interval for the difference, 41.2–62.0) or ibuprofen (31.2–56.5) and similar to cephalexin (−15.6 to 7.4). Response to pivmecillinam was demonstrated in uUTIs caused by Enterobacterales, including E. coli, P. mirabilis, and Klebsiella pneumoniae, as well as gram-positive S. saprophyticus. Conclusions: This reanalysis of randomized, controlled trial data confirmed the efficacy of oral pivmecillinam in uUTI and was used to support its recent approval in the United States.
- 26 June 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (5) , e285-e293
Open AccessPivmecillinam for Treatment of Uncomplicated Urinary Tract Infection: New Efficacy Analysis
Background: In April 2024—over 40 years after its first approval in Europe—pivmecillinam received approval from the United States Food and Drug Administration (FDA) for the treatment of uncomplicated urinary tract infection (uUTI) in women aged ≥18 years, caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. Herein, we describe the reanalysis from previously published clinical trials, conducted in accordance with current FDA efficacy criteria, which formed the basis for this regulatory approval. Methods: Of 14 studies reviewed, 3 randomized, controlled trials offered suitable subject-level data from patients with uUTI treated with 185 mg pivmecillinam 3 times daily for 3–7 days. Efficacy endpoints for reanalysis were rates of overall (composite clinical and microbiological), clinical, and microbiological response in the microbiological intention-to-treat population (urine culture ≥105 colony-forming units/mL; ≤2 microorganism species; no baseline pathogen nonsusceptible to active comparator). Results: Across the 3 primary studies, overall success rates with pivmecillinam at test of cure (Days 7–15) were 62.0%–71.7% (clinical success, 63.5%–82.7%; microbiological success, 74.3%–86.9%). Overall success was higher for pivmecillinam than for placebo (95% confidence interval for the difference, 41.2–62.0) or ibuprofen (31.2–56.5) and similar to cephalexin (−15.6 to 7.4). Response to pivmecillinam was demonstrated in uUTIs caused by Enterobacterales, including E. coli, P. mirabilis, and Klebsiella pneumoniae, as well as gram-positive S. saprophyticus. Conclusions: This reanalysis of randomized, controlled trial data confirmed the efficacy of oral pivmecillinam in uUTI and was used to support its recent approval in the United States.
- Open Access
- 6 June 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (7) , e0049325
Plasma and intrapulmonary pharmacokinetics of cefepime and taniborbactam in healthy adult participants
Cefepime-taniborbactam is being developed for the treatment of serious multidrug-resistant (MDR) Gram-negative bacterial infections. This study determined and compared plasma and epithelial lining fluid (ELF) concentrations of cefepime and taniborbactam in 30 healthy adult participants. The dosing regimen was 2 g cefepime/0.5 g taniborbactam administered as a 4 h intravenous infusion every 8 h for a total of six doses. Mean plasma and ELF concentration values with the four aspirates at each bronchoalveolar lavage (BAL) sampling time (1, 3, 4.25, 5, 6, and 8 h) were used to estimate the area under the concentration-time curve (AUC 0–8 ). The mean AUC 0–8 values of unbound plasma concentrations of cefepime and taniborbactam were 262.2 and 84.77 µg·h/mL, respectively. The drug penetration ratios of ELF to unbound plasma concentrations (DPR ELF/plasma ) were based on the AUC 0–8 values of six different BAL aspirate calculations: single aspirates (for the first, second, third, and fourth BAL sample) and pooled aspirates (BAL samples 2+3+4 and 1+2+3+4). The AUC 0–8 values for ELF for individual and pooled aspirates ranged from 51.62 to 97.86 µg·h/mL for cefepime and 13.14 to 21.69 µg·h/mL for taniborbactam. The DPR ELF/plasma ranged from 0.197 to 0.373 for cefepime and 0.153 to 0.253 for taniborbactam and was dependent on which aspirate of recovered BAL fluid was used. The highest and lowest values of AUC 0–8 values for ELF and DPR ELF/plasma for cefepime and taniborbactam were observed with aspirate 1 and aspirate 4, respectively. These results support further consideration of cefepime-taniborbactam as a potential treatment for bacterial pneumonia caused by susceptible MDR Gram-negative pathogens. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04951505 .
- 6 June 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (7) , e0049325
Open AccessPlasma and intrapulmonary pharmacokinetics of cefepime and taniborbactam in healthy adult participants
Cefepime-taniborbactam is being developed for the treatment of serious multidrug-resistant (MDR) Gram-negative bacterial infections. This study determined and compared plasma and epithelial lining fluid (ELF) concentrations of cefepime and taniborbactam in 30 healthy adult participants. The dosing regimen was 2 g cefepime/0.5 g taniborbactam administered as a 4 h intravenous infusion every 8 h for a total of six doses. Mean plasma and ELF concentration values with the four aspirates at each bronchoalveolar lavage (BAL) sampling time (1, 3, 4.25, 5, 6, and 8 h) were used to estimate the area under the concentration-time curve (AUC 0–8 ). The mean AUC 0–8 values of unbound plasma concentrations of cefepime and taniborbactam were 262.2 and 84.77 µg·h/mL, respectively. The drug penetration ratios of ELF to unbound plasma concentrations (DPR ELF/plasma ) were based on the AUC 0–8 values of six different BAL aspirate calculations: single aspirates (for the first, second, third, and fourth BAL sample) and pooled aspirates (BAL samples 2+3+4 and 1+2+3+4). The AUC 0–8 values for ELF for individual and pooled aspirates ranged from 51.62 to 97.86 µg·h/mL for cefepime and 13.14 to 21.69 µg·h/mL for taniborbactam. The DPR ELF/plasma ranged from 0.197 to 0.373 for cefepime and 0.153 to 0.253 for taniborbactam and was dependent on which aspirate of recovered BAL fluid was used. The highest and lowest values of AUC 0–8 values for ELF and DPR ELF/plasma for cefepime and taniborbactam were observed with aspirate 1 and aspirate 4, respectively. These results support further consideration of cefepime-taniborbactam as a potential treatment for bacterial pneumonia caused by susceptible MDR Gram-negative pathogens. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04951505 .
- Open Access
- 6 November 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (11) , e0110324
Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers
SPR720 is a phosphate ester prodrug that is converted rapidly in vivo to SPR719, the active moiety, which exhibits potent in vitro activity against clinically relevant mycobacterial species including Mycobacterium avium complex (MAC) and Mycobacterium abscessus . SPR720 is in clinical development for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD) due to MAC. This study evaluated the safety and the intrapulmonary pharmacokinetics of SPR719 in healthy volunteers. A total of 30 subjects received oral SPR720 1,000 mg once daily for 7 days followed by bronchoscopy and bronchoalveolar lavage, with blood samples collected for plasma pharmacokinetic assessments. Mean SPR719 area under the concentration-time curve from time 0 to 24 hours (AUC 0–24 ) and maximum concentration ( C max ) for plasma, epithelial lining fluid (ELF), and alveolar macrophages (AM) were 52,418 ng·h/mL and 4,315 ng/mL, 59,880 ng·h/mL and 5,429 ng/mL, and 128,105 ng·h/mL and 13,033 ng/mL, respectively. The ratios of ELF to total plasma concentrations of SPR719 based on AUC 0–24 and C max were 1.14 and 1.26, and the ratios of AM to total plasma concentrations of SPR719 based on AUC 0–24 and C max were 2.44 and 3.02, respectively. When corrected for protein binding, the ratios of ELF to unbound plasma concentrations of SPR719 for AUC 0–24 and C max were 19.87 and 21.88, and the ratios of AM to unbound plasma concentrations of SPR719 for AUC 0–24 and C max were 42.50 and 52.53, respectively. No unexpected safety findings were observed. Results from this study of the intrapulmonary disposition of SPR719 support further investigation of SPR720 as a potential oral agent for the treatment of patients with NTM-PD. This study is registered with Clinicaltrials.gov as NCT05955586 .
- 6 November 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (11) , e0110324
Open AccessIntrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers
SPR720 is a phosphate ester prodrug that is converted rapidly in vivo to SPR719, the active moiety, which exhibits potent in vitro activity against clinically relevant mycobacterial species including Mycobacterium avium complex (MAC) and Mycobacterium abscessus . SPR720 is in clinical development for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD) due to MAC. This study evaluated the safety and the intrapulmonary pharmacokinetics of SPR719 in healthy volunteers. A total of 30 subjects received oral SPR720 1,000 mg once daily for 7 days followed by bronchoscopy and bronchoalveolar lavage, with blood samples collected for plasma pharmacokinetic assessments. Mean SPR719 area under the concentration-time curve from time 0 to 24 hours (AUC 0–24 ) and maximum concentration ( C max ) for plasma, epithelial lining fluid (ELF), and alveolar macrophages (AM) were 52,418 ng·h/mL and 4,315 ng/mL, 59,880 ng·h/mL and 5,429 ng/mL, and 128,105 ng·h/mL and 13,033 ng/mL, respectively. The ratios of ELF to total plasma concentrations of SPR719 based on AUC 0–24 and C max were 1.14 and 1.26, and the ratios of AM to total plasma concentrations of SPR719 based on AUC 0–24 and C max were 2.44 and 3.02, respectively. When corrected for protein binding, the ratios of ELF to unbound plasma concentrations of SPR719 for AUC 0–24 and C max were 19.87 and 21.88, and the ratios of AM to unbound plasma concentrations of SPR719 for AUC 0–24 and C max were 42.50 and 52.53, respectively. No unexpected safety findings were observed. Results from this study of the intrapulmonary disposition of SPR719 support further investigation of SPR720 as a potential oral agent for the treatment of patients with NTM-PD. This study is registered with Clinicaltrials.gov as NCT05955586 .
- Open Access
- 1 April 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209 (7) , 777-778
Lessons Are Still Being Learned about Intrapulmonary Antibiotic Concentrations
- 1 April 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209 (7) , 777-778
Open AccessLessons Are Still Being Learned about Intrapulmonary Antibiotic Concentrations
- Open Access
- 18 July 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (7) , e0042623
Pharmacokinetics of SPR206 in Plasma, Pulmonary Epithelial Lining Fluid, and Alveolar Macrophages following Intravenous Administration to Healthy Adult Subjects
SPR206 is a next-generation polymyxin being developed for the treatment of multidrug-resistant (MDR) Gram-negative infections. This Phase 1 bronchoalveolar lavage (BAL) study was conducted to evaluate SPR206’s safety and pharmacokinetics in plasma, pulmonary epithelial lining fluid (ELF), and alveolar macrophages (AM) in healthy volunteers.
- 18 July 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (7) , e0042623
Open AccessPharmacokinetics of SPR206 in Plasma, Pulmonary Epithelial Lining Fluid, and Alveolar Macrophages following Intravenous Administration to Healthy Adult Subjects
SPR206 is a next-generation polymyxin being developed for the treatment of multidrug-resistant (MDR) Gram-negative infections. This Phase 1 bronchoalveolar lavage (BAL) study was conducted to evaluate SPR206’s safety and pharmacokinetics in plasma, pulmonary epithelial lining fluid (ELF), and alveolar macrophages (AM) in healthy volunteers.
- 19 July 2022
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (7) , e0059022
Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects
Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral carbapenem prodrug being developed for the treatment of serious bacterial infections. The active moiety, tebipenem, has broad-spectrum activity against commonEnterobacteralespathogens, including extended-spectrum-β-lactamase (ESBL)-producing multidrug-resistant strains.
- 19 July 2022
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (7) , e0059022
Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects
Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral carbapenem prodrug being developed for the treatment of serious bacterial infections. The active moiety, tebipenem, has broad-spectrum activity against commonEnterobacteralespathogens, including extended-spectrum-β-lactamase (ESBL)-producing multidrug-resistant strains.
- 4 January 2022
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 61 (2) , 337-338
Authors’ Reply to De Sutter, De Waele, and Vermeulen: “Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update”
- 4 January 2022
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 61 (2) , 337-338
Authors’ Reply to De Sutter, De Waele, and Vermeulen: “Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update”